Low-Dose Pegylated Interferon α-2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus
| العنوان: | Low-Dose Pegylated Interferon α-2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus |
|---|---|
| المؤلفون: | Mikitaka Iguchi, Yoshimasa Maeda, Yoshiyuki Mori, Hideyuki Tamai, Hisanobu Deguchi, Jun Kato, Toru Niwa, Akira Kawashima, Naoki Shingaki, Masao Ichinose, Izumi Inoue, Takao Maekita, Kosaku Moribata |
| المصدر: | Gut and Liver |
| بيانات النشر: | The Editorial Office of Gut and Liver, 2016. |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | Liver Cirrhosis, Male, 0301 basic medicine, viruses, Hepacivirus, Pegylated interferon α, medicine.disease_cause, Polyethylene Glycols, law.invention, chemistry.chemical_compound, Elderly, 0302 clinical medicine, Pegylated interferon, law, Genotype, biology, Gastroenterology, virus diseases, Middle Aged, Recombinant Proteins, Treatment Outcome, Recombinant DNA, Original Article, Drug Therapy, Combination, Female, 030211 gastroenterology & hepatology, medicine.drug, Adult, Hepatitis C virus, Alpha interferon, Interferon alpha-2, Antiviral Agents, Drug Administration Schedule, 03 medical and health sciences, Ribavirin, medicine, Humans, Aged, Hepatology, business.industry, Interferon-alpha, Hepatitis C, Chronic, biology.organism_classification, Virology, digestive system diseases, 030104 developmental biology, ROC Curve, chemistry, business |
| الوصف: | Background/Aims This study aimed to predict sustained viral response (SVR) to low-dose pegylated interferon (PEG-IFN) plus ribavirin of elderly and/or cirrhotic patients with genotype 2 hepatitis C virus (HCV) using viral response within 2 weeks. Methods Low-dose PEG-IFN-α-2b plus ribavirin was administered to 50 elderly and/or cirrhotic patients with genotype 2 HCV for 24 weeks. The dynamics of HCV RNA and HCV core antigen levels within 2 weeks were measured. Results The patients’ median age was 66 years. There were 21 male and 29 female patients. The median baseline HCV RNA level was 5.7 log IU/mL. Rapid viral response was achieved in 17 patients (34%), SVR in 28 (56%), and two (4%) discontinued treatment. Univariate analysis of factors contributing to SVR showed significant differences for sex, baseline virus level, and response within 4 weeks. When 40 fmol/L was set as the cutoff value for the core antigen level at 1 week, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy for predicting SVR were 93%, 75%, 84%, 88%, and 85%, respectively. Conclusions Low-dose PEG-IFN plus ribavirin was a safe and cost-effective treatment for elderly and/or cirrhotic patients with genotype 2 HCV, and the viral response within 2 weeks was a useful predictor of SVR. |
| تدمد: | 2005-1212 1976-2283 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79f4e752e7c87f133f6e785cb25329deTest https://doi.org/10.5009/gnl15193Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....79f4e752e7c87f133f6e785cb25329de |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20051212 19762283 |
|---|